Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: A comparison with imipenem-susceptible VAP

Clinical Infectious Diseases

Volumn 36, Issue 9, 2003, Pages 1111-1118

  Garnacho Montero, José ^a   Ortiz Leyba, C ^a   Jimenez Jimenez F J ^a   Barrero Almodovar A E ^a   Garcia Garmendia J L ^a   Bernabeu Wittell, M ^a   Gallego Lara, S L ^a   Madrazo Osuna, J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BELLON; CARBAPENEM; CILASTATIN PLUS IMIPENEM; COLISTIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MORTALITY; MULTIDRUG RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TOXICITY; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE; MALE; MIDDLE AGED; PNEUMONIA; PROSPECTIVE STUDIES; VENTILATORS, MECHANICAL;

EID: 0038369924     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374337     Document Type: Article

References (39)

1. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94:281-8.
2. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29:2303-9.
3. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001; 33:939-46.
4. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units. Crit Care Med 1999; 27:887-92.
5. Lortholary O, Fagon JY, Buu-Hoy A, et al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995; 20:790-6.
6. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167:448-51.
7. Tankovic J, Legrand P, DeGatines G, et al. Characterization of hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994; 32:2677-81.
8. Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
9. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999; 27:1794-9.
10. NCCLS. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 5th ed. Approved standards document M7-A5. Wayne, PA: NCCLS, 2000.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II, a severity of disease classification system. Crit Care Med 1985; 13:818-29.
12. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996; 22:707-10.
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee. Definition for sepsis and organ failures and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-55.
14. Pittet D, Thiévent B, Wenzel RP, Li N, Gurman G, Suter PM. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 1993; 19:265-72.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1967; 16:31-41.
16. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med 2001; 27:1288-96.
17. Joly-Guillou ML, Wolff M, Pocidalo JJ, et al. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997; 41:345-51.
18. Rodríguez-Hernández MJ, Pachón J, Pichardo L, et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 2000; 45:493-501.
19. Rahal JJ, Urban C. Acinetobacter: epidemiology and control. In: Weinstein RA, Bonten M, eds. Infection control in the ICU environment. Boston: Kluwer Academic Publishers, 2002:67-76.
20. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002; 34:1425-30.
21. Ruiz J, Núñez ML, Pérez J, et al. Evolution of resistance among clinical isolates of Acinetobacter over a 6-year period. Eur J Clin Microbiol Infect Dis 1999; 18:292-5.
22. Manikal VM, Landman D, Saurina G, et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000; 31:101-6.
23. Brun-Buisson C, Sollet JP, Schweich H, et al. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26:346-54.
24. Áldvarez-Lerma F, Insausti-Ordeñana J, Jordá-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27:493-502.
25. Kollef MH, Silver P, Murphy DM, et al. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995; 108:1655-62.
26. Ibrahim EH, Ward S, Sherman G, et al. A comparative analysis of patients with early-onset vs. late-onset nosocomial pneumonia in the ICU setting. Chest 2000; 117:1434-42.
27. Torres A, Bauer TT, León-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem-cilastatin. Thorax 2000; 55:1033-9.
28. Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adults patients with cystic fibrosis. Thorax 1997; 2:987-93.
29. Alvarez-Lerma and the ICU-acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22:387-94.
30. Rello J, Gallego M, Mariscal D, Soñora R, Vallés J. The value of routine microbiological investigation in ventilator-associated pneumonia. Am J Resp Crit Care Med 1997; 156:196-200.
31. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcome: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
32. Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patient with renal disease. N Engl J Med 1962; 266:759-62.
33. Koch-Weser J, Sidel VW, Fedrman EB, et al. Adverse effects of sodium colistimethate. Ann Intern Med 1970; 72:857-68.
34. Conway SP, Etherington C, Munday J, et al. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis. Ann Pharmacother 2000; 34:1238-42.
35. Reed MD, Stern RC, O'Riordan MA, et al. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001; 41:645-54.
36. Lindesmith LA, Baines RD, Bigelow DB, et al. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med 1968; 68:318-27.
37. Montero A, Ariza J, Corbella X, et al. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002; 46:1946-52.
38. Wolff M, Joly-Guillou ML, Farinotti R, et al. In-vivo efficacies of combinations of β-lactams, β-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999; 43:1406-11.
39. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001; 40:117-20.